Dr. Reddy has played an integral role in advancing oncology efforts at Labcorp dedicated to advancing precision oncology to improve patient outcomes. Since joining Labcorp, he oversaw the acquisitions of OmniSeq and PGDx expanding Labcorp’s leading oncology portfolio of NGS-based genomic profiling capabilities. He previously served as VP of Medical Affairs at Foundation Medicine. He is triple board-certified in internal medicine, medical oncology, and hematology. Dr. Reddy earned his medical degree from the University of Kansas Medical Center, where he completed his internal medicine residency and clinical hematology/oncology fellowship. He obtained a master’s degree in public health (MPH) through a NIH Clinical Research Curriculum Award (K30) program and is an alumnus of Harvard Business School. Additionally, he is a fellow of the American College of Physicians. Dr. Reddy is a Lt. Col. in the U.S. Air Force Reserve, with over 17 years of service.
Genomic Profiling Showcase:
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and lives.
Personalized Clinical Decision Support Leveraging Data Driven Insights
Harnessing technologies, increasing therapeutics access, and extracting data insights to improve outcomes and reduce healthcare costs.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.